Compare NVEC & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVEC | ALT |
|---|---|---|
| Founded | 1989 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 437.4M | 421.5M |
| IPO Year | 1995 | 2005 |
| Metric | NVEC | ALT |
|---|---|---|
| Price | $86.32 | $2.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 241.1K | ★ 4.6M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.13% | N/A |
| EPS Growth | 0.96 | ★ 25.37 |
| EPS | ★ 3.14 | N/A |
| Revenue | ★ $26,331,218.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $28.43 | ★ N/A |
| Revenue Growth | 1.76 | ★ 105.00 |
| 52 Week Low | $57.21 | $2.56 |
| 52 Week High | $121.20 | $6.44 |
| Indicator | NVEC | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 39.42 | 43.42 |
| Support Level | $62.17 | $2.62 |
| Resistance Level | $111.64 | $3.15 |
| Average True Range (ATR) | 5.86 | 0.17 |
| MACD | -1.55 | -0.02 |
| Stochastic Oscillator | 6.31 | 12.12 |
NVE Corp is engaged in developing and selling devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store, and transmit information. It manufactures high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. The company's products include Digital sensors, Medical sensors, Rotation Sensors, GT Sensors, Angle Sensors, Analog sensors, MSOP Isolators, Passive-In Transceivers, and others. The company manufactures high-performance spintronic products including sensors and couplers. The company's designs are based on giant magnetoresistance GMR and tunneling magnetoresistance TMR combined with integrated circuitry.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.